Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MGMT | P16455 | 7/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746589 | 0.87 | MGMT (0.43) | CDK1CCNB1CDK2CCNE1FGFR1 | |
| SCHEMBL1566029 | 0.86 | FGFR1 (0.55) | CDK1CCNB1CDK2CCNE1FGFR1 | |
| SCHEMBL14595210 | 0.84 | CDK1 (0.48) | CDK1CCNB1CDK2CCNE1CYP2C19 | |
| SCHEMBL1565553 | 0.82 | FGFR1 (0.56) | CDK1CCNB1CDK2CCNE1FGFR1 | |
| SCHEMBL13746845 | 0.80 | CYP2C19 (0.39) | CDK1CCNB1CDK2CCNE1FGFR1 | |
| SCHEMBL1565558 | 0.79 | FGFR1 (0.57) | CDK1CCNB1CDK2CCNE1FGFR1 | |
| SCHEMBL2606941 | 0.77 | POLB (0.43) | FGFR1CYP2C19POLB | |
| SCHEMBL24383709 | 0.77 | HSP90AB1 (0.51) | CDK1CCNB1CDK2CCNE1CYP2C19 | |
| SCHEMBL22348853 | 0.77 | HSP90AA1 (0.51) | CDK1CCNB1CDK2CCNE1CYP2C19 | |
| SCHEMBL10129844 | 0.76 | POLB (0.43) | CDK1CCNB1CDK2CCNE1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2009105513-A2 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | CDK1 469/4885CCNB1 418/4885CDK2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.